Search by Drug Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y ZClinical Trials for LUCENTIS
- A Study to Evaluate the Efficacy and Safety of Faricimab in Patients With Choroidal Neovascularization Secondary to Pathologic Myopia
- Phase I Study to Assess the Safety and Efficacy of OCU200 for Center-Involved Diabetic Macular Edema (DME)
- Intravitreal Ranibizumab Injection for Aggressive Versus Type 1 Prethreshold Retinopathy of Prematurity
- Safety Study of Zimura™in Combination With Anti-VEGF Therapy in Patients With Neovascular AMD
- A Phase III Study for 601 Versus Ranibizumab in Patients With Branch Retinal Vein Occlusion (BRVO)
- This Study Will Compare the Efficacy and Safety of SCT510A Administered by Intravitreal Injection (IVT) With Ranibizumab in Patients With wAMD
- TAB014 Compared to Lucentis® in Patients With Neovascular Age-related Macular Degeneration
- Efficacy Evaluation Study of BAT5906 and Lucentis® in Patients With Macular Degeneration
- A Study to Evaluate the Efficacy and Safety of MW02 in the Treatment of nAMD
- A Study to Investigate RO7200220 in Combination With Ranibizumab in Diabetic Macular Edema
- A Study to Investigate RO7200220 in Diabetic Macular Edema
- Study on Precision Treatment of Diabetic Retinopathy Macular Edema Guided by Real-time OCT During Operation
- Ranibizumab Vs Bevacizumab for Type 1 Retinopathy of Prematurity
- Compare the Efficacy and Safety of HLX04-O With Ranibizumab in Subjects With wAMD
- Effect of Ranibizumab Versus Bevacizumab on the Macular Perfusion in Diabetic Macular Edema
- Phase I Study to Compare CMAB818 Injection and Lucentis® in Patients With Wet AMD
- A Study To Evaluate CKD-701 and Lucentis® in Patients With Neovascular(Wet) Age Related Macular Degeneration
- Ozurdex in Suboptimal Diabetic Macular Edema Patients
- Brolucizumab vs. Aflibercept for Retinal Angiomatous Proliferation
- Study to Compare Efficacy and Safety of LUBT010 and Lucentis® in Patients With Neovascular AMD
- 601 Versus Ranibizumab in Patients With Central Retinal Vein Occlusion (CRVO)
- 601 Versus Ranibizumab in Patients With Branch Retinal Vein Occlusion (BRVO)
- Response to Oral Lansoprazole of Inorganic Pyrophosphate Levels in Patients With Grönblad-Stranberg Disease (Pseudoxanthoma Elasticum)
- Pre-vitrectomy Intravitreal Ranibizumab for Patients With Proliferative Diabetic Retinopathy Combined With Diabetic Macular Edema
- Combination of Ranibizumab and Targeted Laser Photocoagulation
- Optical Coherence Tomography Angiography (OCTA) - Directed PDT Triple Therapy
- Anti-VEGF Intravitreous Injections for Diabetic Macular Edema in Patients Undergoing Cataract Surgery
- Ranibizumab Treatment for Macular Edema Secondary to Retinal Vein Occlusion
- Management of Patients With Neovascular Age-related Macular Degeneration Undergoing Cataract Surgery
- Multiple Dose Safety and Efficacy of LKA651 in Patients With Diabetic Macular Edema
- Steroid vs. Anti-vascular Endothelial Growth Factor for Diabetic Macular Edema Prior to Phacoemulsification
- Combined Ranibizumab and Iluvien for Diabetic Macular Oedema
- Intravitreal Ranibizumab (Lucentis®) in the Treatment of Non-leaking Macular Cysts in Retinal Dystrophy
- Evaluation of the Safety and Efficacy of ALS-L1023 Administered in Combination With Ranibizumab in Patients With Wet-AMD
- Eylea and Lucentis for Macular Edema in Branch Retinal Vein Occlusion
- Combination of Intravitreal Ranibizumab With or Without Micropulse Laser for the Treatment of DME
- Combination OZURDEX® & EyLea® vs. OZURDEX® Monotherapy in IncompLete-Responders wIth Diabetic Macular Edema
- To Evaluate the Comparative Efficacy of Lucentis (Ranibizumab) 0.5mg Intravitreal Injection in Patients With Diabetic Macular Oedema (DME) With Well Controlled and Poorly Controlled Diabetes Mellitus
- Multicenter Clinical Study of Anti-VEGF Treatment on High Risk Diabetic Retinopathy (DR)
- SD-OCT-guided Intravitreal Ranibizumab Treatment in Choroidal Neovascularization Due to Myopia
- Time Course of Activity Signs at SD-OCT High Frequency Intravitreal Ranibizumab Treatment in CNV Due to AMD
- ZIMURA in Combination With LUCENTIS in Patients With Neovascular Age Related Macular Degeneration (NVAMD)
- Evaluating of the Safety, Pharmacokinetics and Pharmacodynamics of QL1205 and Lucentis® in Patients With Wet AMD
- Safety and Efficacy of AS101 1% Oral Solution in Patients With Neovascular Age-Related Macular Degeneration (AMD)
- Study Assessing the Efficacy and Safety of Intravitreal Injections of DE-122 in Combination With Lucentis® Compared to Lucentis® Monotherapy in Wet Age-related Macular Degeneration Subjects
- A Study to Compare SB11 (Proposed Ranibizumab Biosimilar) to Lucentis in Subjects With Neovascular Age-related Macular Degeneration (AMD)
- Serum Vascular Endothelial Growth Factor in Infants With Intravitreal Ranibizumab
- Analysis of Cytokines in Response to Treatment of Diabetic Macular Edema With 0.3mg Lucentis
- Efficacy of Biweekly Ranibizumab (0.5 mg) for Exudative Macular Degeneration Retinal Edema Refractory to Anti-VEGF
- Combination of Intravitreal Ranibizumab With or Without Macular Laser Photocoagulation for ME Secondary to BRVO
- Changes to the Retina Following Anti-VEGF Treatments for Diabetic Macular Edema
- Intraocular Cytokine in Recurrence of Polypoidal Choroidal Vasculopathy
- Efficacy of Fixed Monthly Dosing of Ranibizumab in Neovascular Age-related Macular Degeneration
- Intravitreal Ranibizumab (Lucentis®) for Neovascular Glaucoma- a Randomized Controlled Study
- 24 Week Study to Compare Systemic VEGF-levels of Ranibizumab and Aflibercept in DME.
- Comparison of PDT Combination With Ranibizumab vs. Ranibizumab Monotherapy in Persistent PCV With Initial Loading Dose
- Intravitreal Injection of Ranibizumab Versus Sham Before Vitrectomy in Patients With Proliferative Diabetic Retinopathy
- Functional and Structural Outcomes in Neovascular Age-related Macular Degeneration
- Effects of Intravitreal Ranibizumab for Macular Edema With Nonproliferative Diabetic Retinopathy
- Initial Versus Delayed PDT Combination With Conbercept in PCV
- Prospective Observational Study to Assess Effectiveness of Intravitreal Aflibercept in Patients With Wet Macular Degeneration in Greece
- Safety and Efficacy of Two Regimens of Ranibizumab 0.5 mg in Chinese Patients With Neovascular AMD
- Subconjunctival Aflibercept (EYLEA®) for the Treatment of Corneal Neovascularization
- Double-dose Ranibizumab for Polypoidal Choroidal Vasculopathy
- Efficacy and Safety Study of Squalamine Ophthalmic Solution in Subjects With Neovascular AMD
- Cytokeratin 8 Level in Age-related Macular Degeneration
- A Study of Faricimab (RO6867461) in Participants With Center-Involving Diabetic Macular Edema
- A Study in Patients With Neovascular Age Related Macular Degeneration or Macular Edema Secondary To Retinal Vein Occlusion to Evaluate Usability of the Ranibizumab (Lucentis®) Prefilled Syringe (PFS)
- Combination OZURDEX® & LUCENTIS® vs. OZURDEX® Monotherapy in Incomplete-Responders With Diabetic Macular Edema
- Efficacy of Ranibizumab Therapy With Aflibercept in Patients With Diabetic Macular Edema
- Intravitreal Aflibercept or Ranibizumab for Rubeosis Iridis
- Macular Edema Ranibizumab v. Intravitreal Anti-inflammatory Therapy Trial
- Study of Squalamine Lactate for the Treatment of Macular Edema Related to Retinal Vein Occlusion
- An Open-Label Investigator Sponsored Trial to Investigate the Safety, Tolerability and Development of Subfoveal Fibrosis By Intravitreal Administration of Altering Regimens of Fovista and Anti-VEGF Therapy in Subjects With Neovascular Age-Related Ma
- Head to Head Study of Anti-VEGF Treatment.
- Study Evaluating the Safety, Pharmacokinetics and Pharmacodynamics of OPT-302 With or Without Lucentis™ in Patients With Wet AMD
- Study of DS-7080a for the Treatment of Macular Degeneration
- Evaluation of the "Treat-and-extend" Scheme in Patients With Retinal Vein Occlusion (RVO) With and Without LASER Treatment of Ischaemic Retinal Areas
- Effect of Squalamine Lactate Ophthalmic Solution, 0.2% in Subjects With Neovascular Age-Related Macular Degeneration
- Ziv-aflibercept in Ocular Disease Requiring Anti-VEGF Injection
- A Proof-of-Concept Study of Faricimab (RO6867461) in Participants With Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD)
- Evaluation of the Usefulness of a PRN Regimen Using Ranibizumab for Macular Edema Due to Branch Retinal Vein Occlusion
- Adjunctive Photodynamic Therapy + Aflibercept vs. Afilbercept Alone for PDA in NV AMD
- The Effect of Intravitreal Ranibizumab on Visual Acuity and Hard Exudate Resolution in the Treatment of Diabetic Macular Edema With Center Involved Edema and Lipid Exudates
- 25-G Vitrectomy With Ranibizumab or Triamcinolone Acetonide on PDR in China-Randomized Clinical Trial
- A Study to Establish the Safety and Tolerability of Zimura® (Anti-C5 Aptamer) in Combination With Anti-VEGF Therapy in Subjects With Idiopathic Polypoidal Choroidal Vasculopathy (IPCV)
- A 24 Month Phase 2a Open Label, Randomized Study of Avastin®, Lucentis®, or Eylea® (Anti-VEGF Therapy) Administered in Combination With Fovista® (Anti-PDGF BB Pegylated Aptamer)
- Study of Efficacy of Ranibizumab in Different Regimens in Patients With Diabetic Macula Edema
- Evaluation of Inflammation and Pain Post Injection of Ranibizumab vs Aflibercept in Patients With DME
- LHA510 Proof-of-Concept Study as a Maintenance Therapy for Patients With Wet Age-Related Macular Degeneration
- Intralesional Ranibizumab on Pterygium Vascularity, Size and Recurrence Rate: a Pilot Study
- Change Oxygen Consumption Following Intravitreal Treatment of Lucentis (Ranibizumab) in Eyes With Diabetic Macular Edema
- Evaluation of the Simplified Treat And Extend Regimen Using Ranibizumab in Exudative Age Related Macular Degeneration
- 25-Gauge Vitrectomy With Ranibizumab or Triamcinolone Acetonide on Proliferative Diabetic Retinopathy in China
- Prophylactic Ranibizumab for Exudative Age-Related Macular Degeneration
- A Study to Evaluate ASP8232 in Reducing Central Retinal Thickness in Subjects With Diabetic Macular Edema (DME)
- Comparison of Pharmacokinetics of and Effect on Systemic VEGF Levels in Age Related Macular Degeneration Patients
- Acute Pseudophakic Cystoid Macular Edema Treatment Trial: Intravitreal Ranibizumab Versus Triamcinolone Acetonide
- Genetic Analysis of Patients Responsive to Ranibizumab But Resistant to Aflibercept
- Comparing Injection Frequency Between Aflibercept and Ranibizumab in Patients With CRVO With a Treat& Extend Regimen
- Compare Safety/Efficacy of Labeled vs Wait-Extend Regimen of Lucentis in Turkish Patients With VI Due to DME
- A 12-month, Randomized, Efficacy and Safety Study of 0.5 mg Ranibizumab vs Laser in Chinese Diabetic Macular Edema (DME) Patients
- Systemic VEGF Protein Dynamics Following Intravitreal Injections of Ranibizumab Versus Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema
- Systemic Vascular Endothelial Growth Factor (VEGF) Protein Dynamics Following Intravitreal Injections of Ranibizumab Versus Aflibercept in Patients With Neovascular Age-related Macular Degeneration
- Stereotactic Radiotherapy for Wet AMD (STAR)
- Study of the Efficacy and Tolerability of Intravitreal Injections of Ranibizumab Compared to Intravitreal Injections of Ranibizumab Combined With Targeted Retinal Photocoagulation to Treat Radiation Retinopathy.
- Cytokine Levels in Patients With Persistent Diabetic Macular Edema Treated With Triamcinolone Acetonide
- Intraocular Cytokines in Non-responders to Ranibizumab Treatment for Neovascular AMD
- Phase 2A Open Label Safety Study of Fovista® (Anti-PDGF BB) Regimen Administered in Combination With Anti-VEGF Therapy to Study Sub-Retinal Fibrosis in Neovascular AMD
- A Pharmacokinetic Study: Ranibizumab, Aflibercept and the Effect of Vitrectomy.
- Development of Intravitreal Ranibizumab by Determining the Pathogenesis of Macular Edema With Retinal Vein Occlusion
- Lucentis to Treat Retinopathy of Prematurity (ROP) 3 Plus Disease
- Aflibercept After Ranibizumab in Exudative Age-related Macular Degeneration
- Prognostic Factors for Visual Improvement in Patients Undergoing Intravitreal Ranibizumab for Retinal Vein Occlusion
- Efficacy and Safety of Lucentis® (Ranibizumab Intravitreal Injections) in Chilean Patients With Diabetic Macular Edema.
- Prophylactic Ranibizumab for Exudative Age-related Macular Degeneration
- A Comparison of Ranibizumab and Aflibercept for the Development of Geographic Atrophy in (Wet) AMD Patients
- Frequent Dosing Regimen of Lucentis for Subjects With Persistent Diabetic Macular Edema Despite Standard antiVEGF Dosing
- Plasma Levels of Vascular Endothelial Growth Factor Before and After Intravitreal Injection of Aflibercept
- Safety Study of PF582 Versus Lucentis in Patients With Age Related Macular Degeneration
- Systemic Pharmacokinetics Following Intravitreal Injections of Anti-VEGF
- Predictive Factors of Ranibizumab Treatment in Macular Edema With CRVO
- Analysis of Aqueous and Vitreous Humor
- Combination of Standard Lucentis Therapy With Micropulse Diode Laser for the Treatment of Diabetic Macular Edema
- Retinal Ganglion Cell Function After Intravitreous Ranibizumab in Patients With Diabetic Macular Edema
- The TIME-2 Study: A Phase 2 Study of AKB-9778, a Novel Tie-2 Activator, in Patients With Diabetic Macular Edema
- Safety and Efficacy Study of BCD-021 Compared to Lucentis® in Patients With Neovascular Wet Age-related Macular Degeneration
- Efficacy and Safety of Lucentis® Use in Patients With Diabetic Macular Edema Evaluating a Spaced Out Follow-up After Intensive Treatment Phase
- Phase 1 Study of Topical Ocular PAN-90806 for Neovascular AMD
- Safety and Efficacy of Ranibizumab for Diabetic Macular Edema
- Ranibizumab Intravitreal Injections Versus Sham Control in Patients With Branch Retinal Vein Occlusion (BRVO)
- Ranibizumab Intravitreal Injections Versus Sham Control in Patients With Central Retinal Vein Occlusion (CRVO)
- Comparison of Treatment Regimens Using Ranibizumab: Intensive (Resolution of Intra- and Sub-retinal Fluid) vs Relaxed (Resolution of Intra-retinal Fluid and/or Sub-retinal Fluid >200µm at the Foveal Centre)
- Efficacy and Safety of Intravitreal Aflibercept Injection for Subacute Central Serous Chorioretinopathy
- Reduced-fluence Verteporfin Photodynamic Therapy Plus Ranibizumab for Choroidal Neovascularization in Pathologic Myopia
- Randomized Study for Efficacy and Safety of Ranibizumab 0.5mg in Treat-extend and Monthly Regimens in Patients With nAMD
- Ozurdex Implant for Macular Edema After Treatment Failure With Anti-VEGF
- Phase II Combination Steroid and Anti-VEGF for Persistent DME
- A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Lucentis® Compared to Lucentis® Monotherapy
- A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Lucentis® Compared to Lucentis® Monotherapy
- A Safety and Efficacy Trial of a Treat and Extend Protocol Using Ranibizumab With and Without Laser Photocoagulation for Diabetic Macular Edema
- Evaluation of Pain and Inflammation After Injection of Lucentis vs Eylea for Treatment of Wet Macular Degeneration
- Efficacy and Safety of Ranibizumab 0.5 vs Verteporfin PDT in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia
- Ranibizumab In Pigment Epithelium Tears Secondary To Age-Related Macular Degeneration Study
- Efficacy Study of Lucentis in the Treatment of Retinoblastoma
- Investigator Sponsored Trial of Polypoidal Choroidal Vasculopathy (PCV) Evaluation Assessing High-Dose Ranibizumab Prospectively (PEARL2)
- ESBA1008 Microvolume Study
- Visual Outcome in Patients With Symptomatic Macular Polypoidal Choroidal Vasculopathy (PCV) Treated With Either Ranibizumab as Monotherapy or Combined With Verteporfin Photodynamic Therapy (vPDT)
- Ranibizumab For Persistent Diabetic Macular Edema After Bevacizumab
- Intravitreal tPA and C3F8 for the Treatment of Submacular Haemorrhage as a Complication of Neovascular AMD
- Ozurdex Versus Ranibizumab Versus Combination for Central Retinal Vein Occlusion
- Use of Intravitreal Ranibizumab in the Treatment of Vitreous Hemorrhage
- Indocyanine Angiographic Changes of Choroidal Neovascularization by Ranibizumab
- Ranibizumab for Macular Edema Secondary to Branch Retinal Vein Occlusion in Patients With Fair Vision
- Treat & Extend Treatment With 0.5mg Ranibizumab vs Monthly Treatment With 0.5mg Ranibizumab
- Intravitreal Ranibizumab Combined With Panretinal Photocoagulation in Patients With Proliferative Diabetic Retinopathy
- Use of Eylea for the Treatment of an Optic Nerve Hemangioma
- Widefield Angiography Guided Targeted-retinal Photocoagulation Combined With Anti VEgf Intravitreal Injections for the Treatment of Ischemic Central Retinal Vein Occlusion, Hemi Retinal Vein Occlusion, and Branch Retinal Vein Occlusion
- Genetic Polymorphisms in Ranibizumab Treatment in Wet Age-Related Macular Degeneration (AMD)
- Bloodstream Absorption of Avastin and Lucentis After Injection Into the Eye
- Anesthesia Preference for Intravitreal Injection: Topical or Subconjunctival
- Treatment of Diabetic Macular Edema With 0.5mg Intraocular Ranibizumab (Lucentis)
- Comparing the Effectiveness and Costs of Bevacizumab to Ranibizumab in Patients With Retinal Vein Occlusions (BRVO)
- Comparing the Effectiveness and Costs of Bevacizumab to Ranibizumab in Patients With Diabetic Macular Edema (BRDME)
- Study to Investigate the Safety and Efficacy of Ranibizumab in Patients With Choroidal Neovascularisation Due to Causes Other Than Age Related Macular Degeneration
- Efficacy and Safety of Ranibizumab With or Without Laser in Comparison to Laser in Branch Retinal Vein Occlusion
- Ozurdex With Rescue Lucentis for Treating Macular Edema Secondary to Retinal Vein Occlusion
- Extension Study to Compare Long-term Efficacy and Safety of Ranibizumab Intravitreal Injections Versus Dexamethasone Intravitreal Implant in Patients With RVO
- Determining the Effect of Antibiotic Drop Prophylaxis on the Conjunctival Flora
- Lucentis KAV Study
- The LIMO Study, Lucentis for Treatment of Uveitic Patients With Refractory Cystoid Macular Oedema
- Efficacy & Safety Trial of Intravitreal Injections Combined With PRP for CSME Secondary to Diabetes Mellitus (DAVE)
- Intraoperative Dexamethasone Implant Improves Outcome of Cataract Surgery With Diabetic Macular Edema
- Study for Recalcitrant Age Related Macular Degeneration
- Study of Bimonthly VEGF Trap-Eye Compared to As-needed Administration or Other Therapy for Exudative Age-Related Macular Degeneration
- Iray for Vascularized Pigment Epithelial Detachment (VPED) Secondary to Age Related Macular Degeneration
- Bevacizumab Versus Ranibizumab for the Treatment of Diabetic Macular Edema
- Dosing Study of Ranibizumab for Diabetic Retinal and Macular Edema
- Analysis of Growth Factors in Patients Undergoing Lucentis or Avastin Injections for Diabetic Macular Edema and Exudative Macular Degeneration
- Ranibizumab in Residual Diabetic Macular Edema Following Previous Anti-VEGF Therapy
- Intravitreal Ranibizumab 0.5MG, or 1.0mg for RVO With Macular Edema Previously Receiving Bevacizumab
- Safety Study of 2.0mg Lucentis to Treat Polypoidal Choroidal Vasculopathy
- Study EvAluating Genotypes While Using Lucentis 2
- Wet AMD Recurrence Rate in Patients Stable on Three Month Ranibizumab Dosing
- Hemodilution Versus Ranibizumab in Early-onset Central Retinal Vein Occlusion
- PF-04523655 Dose Escalation Study, and Evaluation of PF-04523655 With/Without Ranibizumab in Diabetic Macular Edema (DME)
- An Extension Study to Evaluate Safety and Tolerability of Ranibizumab in Macular Edema Secondary to Retinal Vein Occlusion (Cohort 2)
- Safety and Efficacy Study of Ozurdex® Compared to Lucentis® in Patients With Branch Retinal Vein Occlusion
- Efficacy and Safety Study of iSONEP With & Without Lucentis/Avastin/Eylea to Treat Wet AMD
- Ranibizumab for the Management of Recurrent Nosebleeds in Patients With Hereditary Hemorrhagic Telangiectasia (HHT)
- Clinical Assessment Of Age-related Macular Degeneration Patients After Early Diagnosis and Treatment With Ranibizumab
- Efficacy and Safety of Ranibizumab Intravitreal Injections Versus Dexamethasone Intravitreal Implant in Patients With Central Retinal Vein Occlusion (CRVO)
- Study to Evaluate the Effects of Ranibizumab (Lucentis) for Patients With Rubeosis and Neovascular Glaucoma
- Evaluation of Wet Age-Related Macular Degeneration (AMD) Genetic Profile Interactions With Ranibizumab Treatment Outcomes
- Aqueous Humor Level of Cytokines in Polypoidal Choroidal Vasculopathy and Change of Cytokines After Photodynamic Therapy
- High Dose Intravitreal Ranibizumab for Recalcitrant Radiation Retinopathy
- iSONEP to Treat Persistent Pigment Epithelial Detachment (PED) in Subjects With Exudative Age-Related Macular Degeneration (AMD) or Polypoidal Choroidal Vasculopathy (PCV)
- Ranibizumab Versus Low-fluence Photodynamic Therapy in the Treatment of Chronic Central Serous Chorioretinopathy
- Ranibizumab and the Risk of Arterial Thromboembolic Events
- Ranibizumab in Diabetic Vitrectomy. A Prospective, Randomised Controlled Trial of Ranibizumab Pre-treatment in Diabetic Vitrectomy - a Pilot Study
- Ranibizumab "Treat and Extend" in Diabetic Macular Edma
- Ranibizumab 0.5mg and 2.0mg to Treat Diabetic Macular Edema in Patients With Poor Response to Bevacizumab
- Prospective, Randomized, Multicenter, Open Label, Phase II Study to Access Efficacy and Safety of Lucentis® Monotherapy Compared With Lucentis® Plus Panretinal Photocoagulation (PRP) and PRP in the Treatment of Patients With High Risk Proliferativ
- A Study Evaluating Dosing Regimens for Treatment With Intravitreal Ranibizumab Injections in Subjects With Macular Edema Following Retinal Vein Occlusion
- Palomid 529 in Patients With Neovascular Age-Related Macular Degeneration
- Ranibizumab Short- and Log-term Effects on Retinal Function in wAMD
- Evaluation of the Effect of Vitreous Composition Determined by Ultrasound and Optical Coherence Tomography (OCT) on Ranibizumab Therapy
- Serial Retinal Thickness Changes And Scotoma Size Measured With Lucentis Therapy
- Ranibizumab as a Rescue Therapy for Diabetic Macular Edema
- Sub-tenon Triamcinolone Acetonide in Age-Related Macular Degeneration as Adjunct to Ranibizumab
- OZURDEX in Age Related Macular Degeneration as Adjunct to Ranibizumab
- Treatment of Epiretinal Membranes With Ranibizumab
- Pan-VEGF Blockade for the Treatment of Retinopathy of Prematurity (BLOCK-ROP)
- Study of 2.0 mg Ranibizumab in Subjects With Ischemic Central Retinal Vein Occlusion (RAVE2)
- Lucentis (Ranibizumab) in Diabetic Macular Oedema: a Treatment Evaluation
- Genetics in Non-response to Anti-VEGF Treatment in Exudative AMD
- High-Dose Lucentis (Ranibizumab 2.0mg) for the Treatment of Nonproliferative Idiopathic Parafoveal Telangiectasia
- Ranibizumab for Diabetic Traction Retinal Detachment
- HiPED - High Dose Lucentis for Persistent Pigment Epithelial Detachments in Age-related Macular Degeneration
- 20089 TA+Lucentis Combo Intravitreal Injections for Treatment of Neovascular Age-related Macular Degeneration (AMD)
- Intravitreal Macugen for Ischaemic Diabetic Macular Oedema
- French Evaluation Group Avastin Versus Lucentis
- Evaluation of AL-78898A in Exudative Age-Related Macular Degeneration
- Comparison of Safety, Effectiveness and Quality of Life Outcomes Between Labeled Versus "Treat and Extend" Regimen in Turkish Patients With Choroidal Neovascularisation Due to Age-related Macular Degeneration (AMD)
- LUCAS (Lucentis Compared to Avastin Study)
- Efficacy and Safety of Lucentis for Clinically Significant Macular Edema Secondary to Central Retinal Vein Occlusion
- Safety and Efficacy of Dexamethasone as Adjunctive Therapy to Ranibizumab in Subjects With Choroidal Neovascularization and Age-Related Macular Degeneration
- A Pilot Study for the Evaluation of Minocycline as a Microglia Inhibitor in the Treatment of Diabetic Macular Edema
- Panretinal Photocoagulation (PRP) Plus Ranibizumab for Proliferative Diabetic Retinopathy
- A Safety and Efficacy Study of E10030 (Anti-PDGF Pegylated Aptamer) Plus Lucentis for Neovascular Age-Related Macular Degeneration
- Ranibizumab for Edema of the Macula in Diabetes: Protocol 3 With High Dose - the READ 3 Study
- Use of Ranibizumab to Treat Rubeosis in Diabetics Prior to Cataract Surgery
- Preoperative Intravitreal Ranibizumab for Persistent Diabetic Vitreous Haemorrhage:
- Lucentis for Macular Edema Associated With Central Retinal Vein Occlusion
- Ranibizumab in Patients With Branch Retinal Vein Occlusion
- A Study of Intravitreal Injections of 2.0mg Ranibizumab in Subjects With Chronic Fluid On OCT Post Multiple Injections With Ranibizumab (Super-dose Anti-VEgf SAVE Trial)
- Ranibizumab Therapy for Choroidal Neovascularization (CNV) Asociated With Angioid Streaks
- Impact of Lucentis on Psychological Morbidity in Patients With Retinal Vein Occlusion
- Macular EpiRetinal Brachytherapy Versus Lucentis® Only Treatment (MERLOT)
- Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy (N)
- Comparison of Intravitreal Ranibizumab and Macular Grid-pattern Laser for Treatment of Diabetic Macular Edema
- Intravitreal Ranibizumab For Persistent New Vessels In Diabetic Retinopathy(Inipe Study)
- WALTZ - Wet Age-Related Macular Degeneration (AMD) AL-39324 Treatment Examination
- Intravitreal Ranibizumab in Retinal Pigment Epithelial Detachments
- Combination of Ranibizumab and Verteporfin Therapy in Neovascular Age-related Macular Degeneration
- Intravitreal Ranibizumab for the Treatment of Choroidal Neovascularization in Ocular Histoplasmosis Syndrome
- Effect of Intravitreal Ranibizumab Injection With Retinal Vein Occlusion (RVO)
- Lucentis in Advanced Macular Degeneration
- A Study of Ranibizumab Administered Monthly or on an As-needed Basis in Patients With Subfoveal Neovascular Age-related Macular Degeneration (HARBOR)
- Microperimetry and Optical Coherence Tomography (OCT) With Lucentis for Diabetic Macular Edema (DME)
- Use of Pan-Vascular Endothelial Growth Factor Receptor (Pan-VEGF) Blockade for the Treatment of Retinopathy of Prematurity (ROP) (Compassionate Use BLOCK-ROP)
- The Efficacy of Oral Everolimus in Patients With Neovascular Age-related Macular Degeneration
- Study of Uveitic Macular Edema Treated With Ranibizumab or Steroids
- Lucentis to Treat Pigment Epithelial Detachment
- Ranibizumab (Lucentis) for Polypoidal Choroidal Vasculopathy
- Posterior Vitreous Detachment (PVD) Assessment During Dual Retinal Vein Occlusion (RVO) Lucentis Evaluations
- Pilot Study of Ranibizumab (Lucentis) for Uveitic Cystoid Macular Edema
- Efficacy of Ranibizumab in Combination With Photodynamic Therapy for Wet Age-Related Macular Degeneration
- Treatment Of Radiation Retinopathy Trial
- Investigates Improvement in Vision Following Switching From Avastin and Macugen Over to Lucentis
- ERG/EOG Study in AMD Patients Treated With Ranibizumab
- Ranibizumab for the Inhibition of Neovascularization in the Cornea Following Corneal Transplant Surgery
- Ranibizumab for the Inhibition of Neovascularization in Pterygia
- Phase 2 Study of an Ocular Sirolimus (Rapamycin) Formulation in Combination With Lucentis® in Patients With Age-Related Macular Degeneration
- Ranibizumab in Combination With Proton Beam Irradiation for Choroidal Melanoma
- Effect of Intravitreal Ranibizumab on Radiation Retinopathy Following Plaque Brachytherapy for Choroidal Melanoma
- Ranibizumab for Treating Submacular Vascularized Pigment Epithelial Detachments
- VEGF-antagonism and Endothelial Function in Age-related Macular Degeneration (AMD)
- Lucentis for New Onset Neovascular Glaucoma
- Pilot Study Reduced Fluence PDT /Visudyne With Ranibizumab vs Ranibizumab Monotherapy for Exudative Age-related Macular Degeneration (AMD)
- Phase II Open Label Multicenter Study For Age Related Macular Degeneration Comparing PF-04523655 Versus Lucentis In The Treatment Of Subjects With CNV (MONET Study).
- Manta Study: Avastin Versus Lucentis in Age Related Macular Degeneration
- The Effect of a Single Intravitreal Anti-VEGF Therapy on Optic Nerve Head Perfusion
- ARC1905 (ANTI-C5 APTAMER) Given Either In Combination Therapy With Lucentis® 0.5 mg/Eye In Subjects With Neovascular Age-Related Macular Degeneration
- Pan-VEGF Blockade for the Treatment of Retinopathy of Prematurity
- Ranibizumab Injections to Treat Macular Telangiectasia Without New Blood Vessel Growth
- Ranibizumab Injections to Treat Macular Telangiectasia With New Blood Vessel Growth
- Intraocular Anti-VEGF Compared With Intraocular Triamcinolone in Patients With Diabetic Macular Edema
- Effectiveness and Safety of Topical Ranibizumab for Treatment of Corneal Neovascularization (NV)
- Combination Lucentis and Ocular Photodynamic Therapy With Visudyne, With Evaluation-based Retreatment
- Lucentis as an Adjuvant Therapy With TTT-ICG Based in Choroidal Melanoma
- Combined aPproach to Treatment Using Ranibizumab and Efalizumab for Diabetic Macular Edema Study: The CAPTURE DME Study
- Efficacy and Safety of Verteporfin Added to Ranibizumab in the Treatment of Symptomatic Macular Polypoidal Choroidal Vasculopathy
- Intravitreal Ranibizumab to Treat Macular Edema After Panretinal Photocoagulation (Phase II)
- Ranibizumab for Neurofibromas Associated With Neurofibromatosis 1
- Ranibizumab in Preventing Failure of Ahmed Valve Glaucoma Surgery
- The Effects of Bevacizumab and Ranibizumab on Ocular Pulse Amplitude in Neovascular Age Related Macular Degeneration (AMD)
- Lucentis Versus Mitomycin C During Glaucoma Surgery
- Ranibizumab for Treatment of Persistent Diabetic Neovascularization Assessed by Wide-Field Imaging
- The MAP Study: Fluocinolone Acetonide (FA)/Medidur (TM) for Age Related Macular Degeneration (AMD) Pilot
- Comparison of Age-related Macular Degeneration Treatments Trials: Lucentis-Avastin Trial
- Lucentis for Age-related Macular Degeneration Pigment Epithelial Detachments
- Efficacy and Safety Study of Lucentis (Ranibizumab) and Visudyne (Verteporfin) Combination Therapy in Neovascular AMD
- Photodynamic and Pharmacologic Treatment of CNV
- A Phase 1, Safety, Tolerability and Pharmacokinetic Profile of Intravitreous Injections of E10030 (Anti-PDGF Pegylated Aptamer) in Subjects With Neovascular Age-Related Macular Degeneration
- A Randomized Study Comparing Ranibizumab to Sham in Patients With Macular Edema Secondary to CRVO
- Ranibizumab for Branch Retinal Vein Occlusion Associated Macular Edema Study (RABAMES)
- Safety & Efficacy Study Evaluating the Combination of Bevasiranib & Lucentis Therapy in Wet AMD (CARBON)
- Bevacizumab Versus Ranibizumab for Diabetic Retinopathy
- Intravitreal Ranibizumab for the Prevention of Radiation Maculopathy Following Plaque Radiotherapy
- Changes in Retinal Function After Intravitreal Ranibizumab for Age-related Macular Degeneration
- Subretinal Lucentis for Hemorrhagic Age-related Macular Degeneration (AMD)
- MAAM Study: Avastin and Macugen Versus Avastin Versus Macugen
- Pilot Study of Lucentis Combined With Proton Beam Irradiation in Treating Wet Age-related Macular Degeneration
- Ranibizumab to Treat Choroidal Neovascularization (CNV) in Patients With Pseudoxanthoma Elasticum (PXE)
- Ranibizumab to Treat Type 2 Idiopathic Macular Telangiectasia (RAMA-Trial)
- CAPTAIN:Choroidal Neovascularization Assessment by Pattern Electroretinography
- Safety & Efficacy Study Evaluating the Combination of Bevasiranib & Lucentis Therapy in Wet AMD
- Lucentis for Inflammatory Macular Edema Trial
- Reduced Fluence Visudyne-Anti-VEGF-Dexamethasone In Combination for AMD Lesions (RADICAL)
- A Study of the Efficacy and Safety of Ranibizumab Injection in Patients With Macular Edema Secondary to Branch Retinal Vein Occlusion (BRAVO)
- A Study of the Efficacy and Safety of Ranibizumab Injection in Patients With Macular Edema Secondary to Central Retinal Vein Occlusion (CRUISE)
- Study Evaluating Genotypes Using Lucentis
- Reduced Fluence Photodynamic Therapy (PDT) With Visudyne in Combination With Lucentis for Age-Related Macular Degeneration
- A Study of Ranibizumab Injection in Subjects With Clinically Significant Macular Edema (ME) With Center Involvement Secondary to Diabetes Mellitus (RIDE)
- A Study of Ranibizumab Injection in Subjects With Clinically Significant Macular Edema (ME) With Center Involvement Secondary to Diabetes Mellitus (RISE)
- Treatment of Exudative and Vasogenic Chorioretinal Diseases Including Variants of AMD and Other CNV Related Maculopathy
- A Study of Genetic and Environmental Factors and Their Effect on Response to Treatment With Lucentis (Ranibizumab) for Wet AMD
- Scotoma Reduction in AMD Patients Treated With Ranibizumab
- Second Line Therapy to Treat Age-related Macular Degeneration (AMD) for Patients Not Responding Well to Lucentis Therapy by Itself
- Effect of Ranibizumab on Malignant Conjunctival Neoplasia
- Study of Treatment Effects of Combination Therapy of Lucentis Plus Reduced Fluence PDT With Visudyne in Patients With Exudative AMD
- A Study of Strontium90 Beta Radiation With Lucentis to Treat Age-Related Macular Degeneration
- Laser-Ranibizumab-Triamcinolone for Proliferative Diabetic Retinopathy
- Efficacy/Safety of Verteporfin Photodynamic Therapy and Ranibizumab Compared With Ranibizumab in Patients With Subfoveal Choroidal Neovascularization
- Verteporfin Photodynamic Therapy Administered in Conjunction With Ranibizumab in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration (AMD)
- Study Comparing Ranibizumab Monotherapy With Combined Verteporfin Therapy in Subfoveal CNV
- Lucentis Utilizing Visudyne (LUV Trial) Combination Therapy in the Treatment of Age-Related Macular Degeneration
- Immediate Effects of Lucentis® in Conjunction With Photodynamic Therapy With Visudyne® in Exudative AMD(IECOMB)
- The Ranibizumab for Edema of the mAcula in Diabetes-2 (READ-2) Study
- Ranibizumab (Lucentis) for Macular Edema Secondary to Vein Occlusions
- Lucentis for Central Retinal Vein Occlusion (CRVO)
- Efficacy of Retreatments With Intravitreal Bevacizumab
- Rubeosis Anti-VEGF (RAVE) Trial for Ischemic Central Retinal Vein Occlusion
- Intravitreal Ranibizumab Treatment of Central Serous Chorioretinopathy
- Imatinib Mesylate Combined With Intravitreal Ranibizumab in the Treatment of Choroidal Neovascularization Secondary to Age-Related Macular Degeneration
- Intravitreal Ranibizumab Treatment of Central Retinal Vein Occlusion With Macular Edema
- Intravitreal Bevacizumab for Retinal Disorders
- Study To Determine Safety/Efficacy of Lucentis For Treatment Of Retinal Angiomatous Proliferation Secondary To Age Related Macular Degeneration
- Triple Therapy - PDT Plus IVD and Intravitreal Ranibizumab Versus Lucentis Monotherapy to Treat Age-Related Macular Degeneration
- Efficacy Study of Lucentis in the Treatment of Diabetic Macular Edema
- Lucentis (Ranibizumab) for Eales' Disease
- Ranibizumab in Idiopathic Parafoveal Telangiectasia (RIPT) Trial
- An OCT-Guided Variable Dosing Regimen With Ranibizumab for the Treatment of Neovascular AMD
- Ranibizumab in Hemorrhagic Choroidal Neovascularization Trial
- Prospective OCT Study With Lucentis for Neovascular AMD (PrONTO Study)
- Safety and Efficacy of Ranibizumab in Japanese Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration
Clinical trials list
click for details